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Objectives: To analyze the behavior of meningococcal disease in the Federal District, Brazil,
from 2005 to 2011, and to assess the direct impact of the meningococcal serogroup C con-
jugate vaccine.
Methods: A descriptive study of cases of meningococcal disease among residents of the Fed-
eral  District. We  included in the study conﬁrmed cases of meningococcal disease reported
to  the local surveillance. To reduce underreporting we compared data to the Brazilian Mor-
tality  Database and the Public Health Laboratory Database. We  studied sociodemographic,
clinical, and pathogen-related variables. For the assessment of the impact of meningococ-
cal  serogroup C conjugate vaccine, which was introduced in 2010 for children under two
years of age, we compared the incidence of meningococcal disease before and after vaccine
introduction in the recommended age groups for vaccination.
Results: We  identiﬁed 309 cases of meningococcal disease, of which 52.1% were males. The
average case fatality rate was 20.7%, the median age was three years and there was a pre-
dominance of serogroup C (70.2%) and C:23:P1.14-6 phenotype throughout the study period.
In  2005–2009, 2010 and 2011, the incidence rates of meningococcal disease were 2.0, 1.8
and 0.8/100,000 inhabitants/year, while mortality rates were 0.4, 0.4 and 0.2/100,000 inhab-itants/year, respectively. In the ﬁrst and last periods, the incidence in poorer and more
afﬂuent areas were, respectively, 2.0 and 0.8, and 0.9 and 0.0/100,000 inhabitants/year. Com-
paring 2009 (the year prior to the introduction of meningococcal serogroup C conjugate
vaccine) and 2011, there was 85% reduction in the incidence of serogroup C meningococcal
disease in children under four years of age, from 9.0 to 1.3/100,000 (p < 0.01).
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E-mail address: mctauil@yahoo.com.br (M.d.C. Tauil).
ttp://dx.doi.org/10.1016/j.bjid.2013.11.012
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Conclusions: The meningococcal serogroup C conjugate vaccine strategy implemented in
Brazil  proved highly effective and had a strong direct impact on the target population. How-
ever, case fatality rates of meningococcal disease remain high with a wide gap in the risk
of  disease between poor and afﬂuent areas, pointing to the need to reexamine the current
strategy on a regular base.
© 2014 Elsevier Editora Ltda. All rights reserved.Introduction
Meningococcal disease (MD) is one of the most feared human
infectious diseases, mainly due to its rapid progression and
high case fatality rate even with adequate treatment.1
MD  has high incidence rates in Brazil and epidemic dis-
ease waves  have been reported especially of serogroups B and
C. The most dramatic epidemic of MD  occurred in the early
1970s when there was an overlapping of two epidemic waves,
one caused by serogroup A and another caused by serogroup
C. This epidemic outbreak reached its peak in 1974 when 179
cases/100,000 inhabitants/year were reported in the state cap-
ital of São Paulo.2,3
Brazil has reported epidemics of MD associated with
serogroup C since 2005,4,5 with case fatality rates around
20%, high incidence rates among children under two years
old (around 8.0/100,000 inhabitants/year) and nearly 40% of
the cases occurring in children under four years old.5 In
2010, Brazilian health authorities introduced routine vaccina-
tion with the meningococcal serogroup C conjugate vaccine
(MCCV).6 However, unlike other countries, Brazil has imple-
mented a vaccination strategy targeting only children under
two years of age, but no mass vaccination of adolescents.7,8
Given the MD burden in Brazil5 and to better understand
the impact of the vaccination strategy implemented, we  con-
ducted a study to examine MD  occurrence in the Federal
District from 2005 to 2011 and to assess the direct impact
of the introduction of MCCV on the targeted age group for
vaccination.
Materials  and  methods
This is a descriptive study conducted in the Federal District
of Brazil, which is located in the central-west region of the
country and is divided into 30 administrative areas9,10 with
an estimated population of 2,600,000 people (2011). Although
it has the ninth highest human development index (HDI) in
Brazil (0.824),11 there are signiﬁcant social disparities among
administrative areas. The illiteracy rate among people older
than 15 years ranges between 0.6% and 8.0%; the proportion of
households served by sewage treatment systems ranges from
4.2% to 91.8%; and the average monthly per capita income
varies from 0.4 to 10.8 minimum wages.12
Conﬁrmed case of MD  was deﬁned as a person residing in
the Federal District with symptom onset between January 1,
2005 and December 31, 2011 and clinical manifestations con-
sistent with MD  who  met  at least one of the following criteria:
isolation of Neisseria meningitidis from the cerebrospinal ﬂuid(CSF) or blood; positive immunodiagnostic test for N. meningi-
tidis antigen in the CSF or blood; presence of Gram-negative
diplococcus in the CSF; or association or not of purpura fulmi-
nans with meningitis. All cases that met  the inclusion criteria
were included in the study.
We  studied sociodemographic (gender, age, area of resi-
dence), clinical (clinical presentation, progression, and time
[in days] from symptom onset to discharge/death; diagnostic
criterion and time [in days] from symptom onset to hospital-
ization), and pathogen-related variables (serogroup, serotype
and serosubtype) and time of disease occurrence (month and
year).
MD passive surveillance data were obtained from the
National Notiﬁable Disease Database (SINAN); diagnostic data
from the Central Public Health Laboratory of the Federal
District (LACEN-DF) and Instituto Adolfo Lutz of São Paulo
(IAL)/National Reference Center for Meningitis; mortality data
from the National Mortality Database (SIM); and population
data from the Brazilian Institute of Geography and Statistics
(IBGE).9
For creating a database, we  used data from SINAN and per-
formed consistency analysis and duplicate elimination. We
then compared them to data from the LACEN-DF/IAL database
to address missing data. Our prior database was then man-
ually linked with deaths reported in the SIM database for
the study period coded A39.0 (meningococcal meningitis) and
A39.2 (acute meningococcemia).13 Deaths that were found
only in the SIM database were included in the study database.
Cases that had missing information on progression and were
not in the SIM database were considered as cure.
Data  analysis
We ﬁrst conducted a descriptive analysis to describe cases
according to the variables of interest. Categorical variables
were compared using the chi-square test.
For the estimation of incidence and mortality rates, we
used conﬁrmed cases of MD and deaths from MD  as numera-
tor, respectively, and the estimated population at the midpoint
of the study period as denominator. For the calculation of the
average annual incidence and mortality rates, we  divided the
period incidence or period mortality rate of MD by the number
of years in that period. For the estimation of case fatality rates,
we used the total number of deaths from MD as numerator and
the total number of conﬁrmed cases of MD as denominator.The MCCV was introduced in the Federal District in August
2010. From September to December 2010, the vaccine was rec-
ommended for children between three months and two years
of age. Since 2011, the vaccine schedule changed to children
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nder one year of age, with two doses of vaccine given by three
nd ﬁve months of age, and a booster dose by 12 months. For
he assessment of the direct impact of MCCV, we  estimated
otal incidence of MD  and by age group for the years 2009
nd 2011. We  also compared incidence rates of serogroups B
nd C before and after vaccine introduction, by age group. The
nalyses were conducted with the use of SPSS version 20 and
icrosoft Ofﬁce Excel® 2007.
This study was approved by the Research Ethics Com-
ittees of the Health Department of the Federal District
protocol number 373/11) and the Universidade de São
aulo School of Public Health (Plataforma Brasil – CAAE:
1431312.8.0000.5421).
esults
rom 2005 to 2011, we  identiﬁed 309 cases of MD that met  the
tudy inclusion criteria. Of these, 178 (57.6%) were conﬁrmed
y culture, 94 (30.4%) by a clinical criterion, 18 (5.8%) by latex
est, 17 (5.5%) by bacteroscopic examination, and 2 (0.6%) by
ounterimmunoelectrophoresis.
Median time from symptom onset to hospitalization was
ne day (ranging from less than 24 h to ﬁve days) and median
ime from symptom onset to the outcome (discharge/death)
as  10 days (ranging from less than 24 h to 123 days). These
ata refer to cases with information available, i.e., 274 and 266
f the 309 cases studied. The most common clinical presenta-
ions of MD  were meningococcal meningitis (35.1%; 100/285)
nd meningococcal meningitis with meningococcemia (35.8%;
02/285).
Of the 309 individuals with MD, 52.1% were male. From 2005
o 2009, 40.0% of cases of MD  occurred in children under two
nd 23% were two to four years of age; in 2010, these pro-
ortions were 20% and 22.2%, and in 2011, 28.6% and 28.6%
Table 1). The median age in the three time periods (2005–2009,
010 and 2011) were three years (range: nine days to 78 years),
ve years (range: one month to 66 years), and four years (range:
 months to 77 years), respectively.
The average annual incidence rate was 2.0/100,000 inhabi-
ants/year (range: 1.3–2.5 per 100,000) from 2005 to 2009 and 1.8
nd 0.8/100,000 inhabitants/year in 2010 and 2011. The average
nnual incidence rates in children under one year of age were
0.6, 13.3 and 13.1/100,000 inhabitants/year and in children
ith two years of age were 14.4, 10.8 and 2.7/100,000 inhabi-
ants/year from 2005 to 2009 and in 2010 and 2011, respectively
Fig. 1).
The average annual mortality rate was 0.4 (range: 0.3–0.5)
rom 2005 to 2009, 0.4 in 2010 and 0.2/100,000 inhabitants/year
n 2011. The average annual mortality rate in children under
ne year and one year of age were 6.5 and 2.8/100,000 inhabi-
ants/year, respectively, from 2005 to 2009. In 2011, no deaths
n children under ﬁve years of age were reported (Table 1).
Of cases with information available for serogroup, 70.2%
85/121) were serogroup C from 2005 to 2009, 77.8% (14/18)
n 2010, and 60.0% (6/10) in 2011 (Table 1). The incidence
ates of serogroup C infection ranged from 0.2 to 1.0/100,000
nhabitants/year (Fig. 2). During the study period (2005–2011),
erogroup B infection accounted for 19.5% (29/149) of cases,
ith decreasing incidence of cases associated with this4;1 8(4):379–386 381
serogroup over time. Serogroups Y and W135 accounted for
4.1% (6/149) and 6.1% (9/149) of cases. The most common phe-
notype of serogroup C was C:23:P1.14-6 in the three time points
studied (Table 1).
The average case fatality rate for the period 2005–2011 was
20.7%, with no signiﬁcant variation. However, these rates were
not homogeneous among the hospitals treating cases of MD.
Of 25 hospitals, a subset of 13 hospitals showed an average
case fatality rate of 38.1% and treated no more  than three
cases during the study period; of these, ﬁve were public hos-
pitals; and three had neonatal, pediatric and adult intensive
care units (ICUs). Another subset of nine hospitals showed an
average case fatality rate of 21.7% and treated six to 18 cases
during the study period; of these, seven were public hospitals;
and three had ICUs. The three remaining hospitals showed an
average case fatality rate of 15.3%; they provided care to 45–58
cases; all of them were public hospitals; and two  had ICUs.
A comparison of the three subsets of hospitals showed that
case fatality rates decreased as the average number of cases
treated in a hospital, the number of public hospitals and avail-
ability of ICUs increased. These differences were statistically
signiﬁcant (p = 0.05; chi square for trend).
The incidence of MD varied by administrative area of resi-
dence according to the average per capita income (in monthly
minimum wages, MMWs). From 2005 to 2009, the incidence
of MD was 2.5 times greater in those living in areas with per
capita income of up to two MMWs (1 MMW  = US$ 200) than in
those residing in areas with income of more  than ﬁve MMWs
(p < 0.001). In 2011, the incidence of MD declined by 50% among
those living in areas with per capita income of up to two
MMWs  and no cases of MD were reported among the most
afﬂuent population (Table 1). Residents of areas of low per
capita income accounted for 73.9% of the Federal District pop-
ulation, while those of middle income with three to ﬁve MMWs
and more  than ﬁve MMWs accounted for 10.2% and 12.4% of
the population, respectively. Information about this indicator
was available for 26/30 administrative areas.
To assess the potential impact of MCCV, we  compared inci-
dence rates before (2009) and after (2011) vaccine introduction.
There was a 68% decline in overall incidence of MD, i.e., from
2.5 to 0.8/100,000 inhabitants/year (p < 0.001). During this same
time period, the incidence of MD in children under two  and
children aged two years fell from 23.6 to 7.9 (66.5%; p = 0.02)
and from 13.5 to 2.7/100,000 inhabitants/year (80.0%; p = 0.19),
respectively (Table 2).
In addition, during this same time period, there was a sig-
niﬁcant reduction of 80% in total cases of MD due to serogroup
C, i.e., from 1.0 to 0.2/100,000 inhabitants/year (p < 0.001). The
incidence rates in children under two and children aged two
years fell from 12.4 to 2.6 (79.0%) and from 6.8 to zero (100%),
respectively (Table 2). The overall reduction in MD  cases by
serogroup C among children under four years of age was
85.6%, from 9.0 to 1.3/100,000 inhabitants/year (p < 0.01). A sim-
ilar reduction (81.6%) was seen among those aged four years
(p = 0.17).
Following vaccine introduction monthly incidence rates of
MD did not exceed 0.15/100,000 inhabitants/year (Fig. 3). The
incidence rates remained at a lower level than that reported
prior to the beginning of the serogroup C epidemic, but with
the typical seasonal pattern of MD.
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Table 1 – Incidence, mortality and case fatality rates of meningococcal disease at different times according to sociodemographic and pathogen-related variables. Federal
District, Brazil.
Variables 2005–2009 2010 2011
Cases
N = 243a
Deaths
N = 50a
Fatality
rate
Cases
N = 45a
Deaths
N = 9a
Fatality
rate
Cases
N = 21a
Deaths
N = 5a
Fatality
rate
N (%) Rateb N (%) Rateb % N (%) Rateb N (%) Rateb % N (%) Rateb N (%) Rateb %
Gender
Male 126 (51.9) 2.2 21 (42) 0.4 16.7 23 (51.1) 1.9 6 (66.7) 0.5 26.1 12 (57.1) 1.0 2 (40) 0.2 16.7
Female  117 (48.1) 1.8 29 (58) 0.5 24.8 22 (48.9) 1.6 3 (33.3) 0.2 13.6 9  (42.9) 0.7 3 (60) 0.2 33.3
Total  243 (100) 2.0 50 (100) 0.4 20.6 45 (100) 1.8 9 (100) 0.4 20.0 21 (100) 0.8 5 (100) 0.2 23.8
Age  (years)
<1  66 (27.2) 30.6 14 (28) 6.5 21.2 5 (11.1) 13.3 4 (44.4) 10.6 80.0 5  (23.8) 13.1 0 (0.0) 0.0 0.0
1–2  31 (12.8) 14.4 6 (12) 2.8 19.4 4 (8.9) 10.8 1 (11.1) 2.7 25.0 1  (4.8) 2.7 0 (0.0) 0.0 0.0
2–5  56 (23.0) 8.7 9 (18) 1.4 16.1 10 (22.2) 8.8 1 (11.1) 0.9 10.0 6  (28.6) 5.2 0 (0.0) 0.0 0.0
5–15 42  (17.3) 1.9 4 (8) 0.2 9.5 13 (28.9) 3.1 2 (22.2) 0.5 15.4 4  (19.0) 0.9 2 (40.0) 0.5 50.0
15–30  25 (10.3) 0.7 6 (12) 0.2 24.0 4 (8.9) 0.5 1 (11.1) 0.1 25.0 3  (14.3) 0.4 1 (20.0) 0.1 33.3
≥30  23 (9.5) 0.4 11 (22) 0.2 47.8 9 (20) 0.7 0 (0.0) 0.0 0.0 2  (9.5) 0.2 2 (40.0) 0.2 100
Total  243 (100) 2.0 50 (100) 0.4 20.6 45 (100) 1.8 9 (100) 0.4 20.0 21 (100) 0.8 5 (100) 0.2 23.8
Serogroup
B  25 (20.7) 0.2 1 (7.7) 0.01 4.0 2 (11.1) 0.1 0 (0.0) 0.0 0.0 2  (20.0) 0.1 0 (0.0) 0.0 0.0
C  85 (70.2) 0.7 10 (76.9) 0.1 11.8 14 (77.8) 0.5 2 (66.7) 0.1 14.3 6  (60.0) 0.2 2 (50.0) 0.1 33.3
Y  4 (3.3) 0.03 0 (0.0) 0.0 0.0 1 (5.6) 0.04 0 (0.0) 0.0 0.0 1  (10.0) 0.04 1 (25.0) 0.04 100
W135  7 (5.8) 0.1 2 (15.4) 0.02 28.6 1 (5.6) 0.04 1 (33.3) 0.04 100 1  (10.0) 0.04 1 (25.0) 0.04 100
Total  121 (100) 1.0 13 (100) 0.1 10.7 18 (100) 0.7 3 (100) 0.12 16.7 10 (100) 0.38 4 (100) 0.15 40.0
Phenotypes
C:23:P1.14-6  47 (38.8) 0.4 4 (30.8) 0.03 8.5 8 (44.4) 0.3 1 (33.3) 0.04 12.5 6  (60.0) 0.2 2 (50.0) 0.1 33.3
C:2a:P1.5.2  19 (15.7) 0.2 1 (7.7) 0.01 5.3 0 (0.0) 0.0 0 (0.0) 0.0 0.0 0  (0.0) 0.0 0 (0.0) 0.0 0.0
C:23:NT  6 (5.0) 0.05 0 (0.0) 0.0 0.0 4 (22.2) 0.2 1 (33.3) 0.04 25.0 0  (0.0) 0.0 0 (0.0) 0.0 0.0
C:  Other Ptc 13 (10.7) 0.1 5 (38.5) 0.04 38.5 2 (11.1) 0.1 0 (0.0) 0.0 0.0 0  (0.0) 0.0 0 (0.0) 0.0 0.0
B:4,7:P1.19,15  15 (12.4) 0.1 0 (0.0) 0.0 0.0 0 (0.0) 0.0 0 (0.0) 0.0 0.0 1  (10.0) 0.04 0 (0.0) 0.0 0.0
B:  Other Ptc 10 (8.3) 0.08 1 (7.7) 0.01 10.0 2 (11.1) 0.1 0 (0.0) 0.0 0.0 1  (10.0) 0.04 0 (0.0) 0.0 0.0
Y/W135d 11 (9.1) 0.09 2 (15.4) 0.02 18.2 2 (11.1) 0.1 1 (33.3) 0.04 50.0 2  (20.0) 0.1 (50.0) 0.1 100
Total  121 (100) 1.0 13 (100) 0.1 10.7 18 (100) 0.7 3 (100) 0.12 16.7 10 (100) 0.38 4 (100) 0.15 40.0
Incomee
≤2 MMWs 187 (86.2) 2.0 40 (81.6) 0.4 21.4 36 (90.0) 1.9 8 (88.9) 0.4 22.2 18 (94.7) 0.9 4 (100) 0.2 22.2
3–5  MMWs 16 (7.4) 1.3 7 (14.3) 0.6 43.8 1 (2.5) 0.3 0 (0.0) 0.0 0.0 1  (5.3) 0.4 0 (0.0) 0.0 0.0
>5  MMWs 14 (6.5) 0.8 2 (4.1) 0.1 14.3 3 (7.5) 1.0 1 (11.1) 0.3 33.3 0  (0.0) 0.0 0 (0.0) 0.0 0.0
Total  217 (100) 1.8 49 (100) 0.4 22.6 40 (100) 1.6 9 (100) 0.4 22.5 19 (100) 0.8 4 (100) 0.2 21.1
a The difference between the total number of cases studied in each period and the total number of cases analyzed in each variable expresses the cases without information.
b Incidence and mortality rates/100,000 inhabitants/year.
c Other Pt, other phenotype.
d Phenotypes: W135:2a:P1.2; W135:15:P1.16; W135:NT:P1.2; W135:2a:P1.5; W135:4,10:P1.16; W135:2a:P1.5,2; W135:2b:P1.2; W135:NT:P1.5,2; Y:19:NT; Y:NT:P1.5,2; Y:NT:P1.2; Y:19,14:NT; Y:15:P1:5,2;
Y:21:P1.5,2.
e Per capita income: in monthly minimum wages (MMWs) by group of administrative area/source: Pesquisa Distrital por Amostra de Domicílios – SEPLAN/CODEPLAN – 2004.
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Fig. 1 – Incidence rate of meningococcal disease by age group at different time points. Federal District, Brazil, 2005–2011.
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Fig. 2 – Total incidence rates and incidence rates of meningococcal disease by serogroups B, C, Y, W135. Federal District,
Brazil, 2005–2011.
Table 2 – Incidence rates before and after the introduction of the meningococcal serogroup C conjugate vaccine. Federal
District, Brazil.
Age All cases Serogroup C Serogroup B
2009
Ratea
(cases)
2011
Ratea
(cases)
Variation
%
2009
Ratea
(cases)
2011
Ratea
(cases)
Variation
%
2009
Ratea
(cases)
2011
Ratea
(cases)
Variation
%
<2 23.6 (21) 7.9 (6) −66.5 12.4 (11) 2.6 (2) −79.0 2.2 (2) 2.6 (2) +18.2
2 13.5 (6) 2.7 (1) −80.0 6.8 (3) 0.0 (0) −100 0 (0) 0.0 (0) –
3 9.0 (4) 7.8 (3) −13.3 4.5 (2) 0.0 (0) −100 2.3 (1) 0.0 (0) −100
4 15.9 (7) 5.0 (2) −68.5 13.6 (6) 2.5 (1) −81.6 0 (0) 0.0 (0) –
5–19 1.6 (11) 0.8 (5) −50.0 0.1 (1) 0.3 (2) +200 0.1 (1) 0.0 (0) −100
≥20 0.9 (15) 0.2 (4) −77.8 0.2 (4) 0.1 (1) −50.0 0 (0) 0.0 (0) –
Total 2.5 (64) 0.8 (21) −68.0 1.0 (27) 0.2 (6) −80.0 0.2 (4) 0.1 (2) −50.0
a Average annual incidence rate per 100,000 inhabitants, and number of cases in parentheses.
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Discussion
The study results showed that MD was a major public health
problem in the Federal District due to its morbidity and mor-
tality especially before the introduction of MCCV. The extent
of MD  in a community has been strongly associated with
local living conditions,14 so these results were unexpected
considering that the Federal District has one of the highest
HDIs in Brazil.11 However, they may be largely explained by
social inequalities; it was evidenced that incidence rates of
MD in poor areas were 2.5 times higher than those reported in
more afﬂuent areas. These risk differences persisted though
at lower levels even after vaccine introduction.
The average annual incidence rate of MD in the Federal
District before vaccine introduction was slightly greater than
the national average5 and even ﬁve times greater than those
reported in other Latin American countries such as Argentina,
Chile, and Venezuela.15
Children under two years of age showed a high risk of
MD, which is consistent with that reported in the literature
regardless of the level of development of the country.16–18 This
ﬁnding is also in agreement with the fact that MD was the
third leading cause of death from infectious and parasitic dis-
eases and the ninth leading cause of hospitalization among
children under ﬁve years of age in the Federal District from
2005 to 2011.19
The study showed that children aged under two years are
at higher risk of death from MD, which is corroborated by the
literature.20 However, we found lower rates than other Brazil-
ian studies.14,16
The case fatality rate of MD in the Federal District was
similar to the average rate nationwide and in some Brazilian
capitals14,20 but it was two times higher than that reported in
developed countries and other South American countries.15
Some authors have argued that it may be due to difﬁculties
to ensure uniformity in the quality of medical care.21–23 This
is further supported by the fact that case fatality rate of MD,
in our study, varied among hospitals and was associated with
average number of cases treated in a given hospital, type of
hospital (public or private), and availability of ICU.Similar to that seen in other Brazilian regions,5 we  also
identiﬁed during the study period an epidemic wave  of MD due
to serogroup C that accounted for more  than two-thirds of the disease. Federal District, Brazil, 2005–2011.
cases reported. This epidemic wave  was predominantly asso-
ciated with two main phenotypes: C:23:P1.14-6 (most cases)
and C:2a:P1.5,2.4,24
Serogroup B was the second major cause of MD during the
study period though it showed a steady decline parallel to
that seen nationwide.5 Serogroups Y and W135 should also
be mentioned. Serogroup Y is an important cause of MD  in
North America,25 while serogroup W135 is more  relevant to
our scenario because it showed greater proportion in the Fed-
eral District than nationwide average5 and had a signiﬁcantly
higher case fatality rate than other serogroups.26–28 In Chile,
serogroup W135 is causing an epidemic of MD since 2012 with
a case fatality of around 25%, which is 2.5 times higher than
the national average fatality rate before this epidemic.29
With regard to the potential direct impact of MCCV, the
analysis evidenced a two-third reduction of the overall inci-
dence of MD, 80% reduction in total cases of MD  due to
serogroup C and 85% reduction in cases due to serogroup C
in cohorts exposed to vaccine. These results strongly support
the effectiveness of the proposed vaccination schedule.
The impact seen on children belonging to the age group tar-
geted for vaccination in the Federal District is similar to that
reported in the United Kingdom, although their strategy cov-
ered individuals aged ﬁve months to 18 years.7 In Spain, on the
other hand, a greater reduction (around 95%)30 was achieved
with vaccination of children aged under ﬁve years but signif-
icant loss of vaccine-induced immunity was evidenced over
time.30
The potential indirect impact of MCCV in children aged
four years requires further investigation and longer follow-
up. In our study, we identiﬁed a reduction of around 81% in
these children. The indirect impact of this vaccine was only
observed in countries that implemented routine vaccination
of children in their ﬁrst year of life combined with mass vac-
cination campaigns targeting individuals up to 20 years of
age.7,8,31,32 The indirect protection effect from MCCV given
to adolescents takes place through eliminating meningococci
from carriers that may expose household contacts.33,34
The study results should be interpreted considering some
limitations. One limitation is the use of secondary sources of
data, which may show inconsistencies of the variables of inter-
est and underreporting. A second limitation is that there may
have been bias toward reporting more  severe cases, which may
have overestimated fatality rates. Another potential limitation
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f this study is the short post-vaccination time analyzed which
ay have prevented a more  consistent assessment of vac-
ine impact. Despite these limitations, our results corroborate
he literature and provide valuable input to improve control
trategies of MD.
In conclusion, the MCCV strategy implemented in Brazil
roved highly effective and had a strong direct impact on
he target population. However, incidence and case fatality
ates of MD remain high with a wide gap in the risk of dis-
ase between poor and afﬂuent areas pointing to the need for
eriodic adjustments and revaluations of the current strategy.
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